A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor

Bullous pemphigoid (BP) is a cutaneous autoimmune blistering disorder. Recently, it has been reported that dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with the development of BP (DPP4i-BP). Patients with DPP4i-BP have autoantibodies (autoAbs) preferentially targeting full-length BP180, b...

Full description

Saved in:

Bibliographic Details
Published in:	Immunological medicine Vol. 44; no. 1; pp. 53 - 55
Main Authors:	Sawada, Kaori, Sawada, Tomoyo, Kobayashi, Tadahiro, Fujiki, Akiko, Matsushita, Takashi, Kawara, Shigeru, Izumi, Kentaro, Nishie, Wataru, Shimizu, Hiroshi, Takehara, Kazuhiko, Hamaguchi, Yasuhito
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis Group 01-03-2021
Subjects:	Aged anti-bp230 ab Autoantibodies bullous pemphigoid Diabetes Mellitus, Type 2 - drug therapy dipeptidyl peptidase-4 inhibitor Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Dystonin - immunology Humans Male Pemphigoid, Bullous - etiology Pemphigoid, Bullous - immunology Time Factors Vildagliptin - administration & dosage Vildagliptin - adverse effects Vildagliptin - therapeutic use dipeptidyl peptidase-4 inhibitor anti-BP230 Ab Bullous pemphigoid
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!